If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Starring a principal cast of Josh Hartnett, Bruce Willis, Lucy Liu, Stanley Tucci, and Ben Kingsley, the film garnered mixed reception. David Mattin of BBC wrote: "Kingsley and Freeman shine individually, but their inevitable, climactic clash of heads lacks force. Like its leading man [Hartnett], this movie presents a charming façade with nothing much underneath." Next, Freeman portrayed himself in the low-budget comedy 10 Items or Less opposite Paz Vega. Two weeks after its theatrical release, 10 Items or Less was made available for download from ClickStar, a film distribution company that Freeman co-founded that year. In 2007, Freeman reprised his role as God in Evan Almighty, a sequel to 2003's Bruce Almighty, with Steve Carell. Evan Almighty was a box-office failure and negatively received; The Guardian critic wrote: "A cast full of people who have been frequently funny elsewhere flounder in this deluge of sentimentality and CGI. Avoid like the Ten Plagues." The drama Feast of Love was Freeman's second release of 2007. It is based on the 2000 novel The Feast of Love by Charles Baxter, about a group of friends living in suburban Oregon who come into contact with a free spirit who changes their outlook on life; Peter Bradshaw of The Guardian sarcastically remarked that it was great to see Freeman in a challenging role. Freeman had a supporting part in Gone Baby Gone (2007), a mystery thriller that was also Ben Affleck's directorial debut. Adapted from the 1998 novel of the same name by Dennis Lehane, Freeman plays Captain Jack Doyle of the Boston Police Department.
== Dental research == Research in oral medicine at the institution can be traced to the medical and dental research section established at West China Union University in 1936. It subsequently developed into an oral-disease research section, the Research Institute of Stomatology in 1958, and a central stomatology laboratory in 1983. In 2007, the Ministry of Science and Technology of China approved the establishment of the State Key Laboratory of Oral Diseases (口腔疾病研究国家重点实验室) at the institution; the laboratory was renamed the State Key Laboratory of Oral Disease Prevention and Control (口腔疾病防治全国重点实验室) in 2023. Other research infrastructure associated with the school and hospital has included the National Clinical Research Center for Oral Diseases (口腔疾病国家临床医学研究中心), an engineering laboratory for oral regenerative medicine, an international cooperative research center, and clinical-trial facilities. The institution is also associated with several academic journals. The International Journal of Oral Science is co-sponsored by the West China School of Stomatology and the State Key Laboratory of Oral Diseases, with its editorial office based at the school. The school also established the journal Bone Research, which is published in partnership with Springer Nature.
The core −C(=O)−(N) of amides is called the amide group (specifically, carboxamide group). In the usual nomenclature, one adds the term "amide" to the stem of the parent acid's name. For instance, the amide derived from acetic acid is named acetamide (CH3CONH2). IUPAC recommends ethanamide, but this and related formal names are rarely encountered. When the amide is derived from a primary or secondary amine, the substituents on nitrogen are indicated first in the name. Thus, the amide formed from dimethylamine and acetic acid is N,N-dimethylacetamide (CH3CONMe2, where Me = CH3). Usually even this name is simplified to dimethylacetamide. Cyclic amides are called lactams; they are necessarily secondary or tertiary amides.
Some colorless compounds such as proteins can be quantified at an Optical Density of 280 nm due to the presence of aromatic rings such as tryptophan, tyrosine and phenylalanine but if none of these amino acids are present then the absorption cannot be measured at 280 nm.
Focal segmental glomerulosclerosis is characterised by a sclerosis of segments of some glomeruli. It is likely to present as a nephrotic syndrome. This form of glomerulonephritis may be associated with conditions such as HIV and heroin abuse, or inherited as Alport syndrome. The cause of about 20–30% of focal-segmental glomerulosclerosis is unknown. On microscopy, affected glomeruli may show an increase in hyalin, a pink and homogeneous material, fat cells, an increase in the mesangial matrix and collagen. Treatment may involve corticosteroids, but up to half of people with focal segmental glomerulonephritis continue to have progressive deterioration of kidney function, ending in kidney failure.
Sources: en.wikipedia.org
=== Diagnosing hEDS === Because no single gene has been identified as the sole cause of the most common type of EDS, the hypermobile type, obtaining a diagnosis is often difficult. The 2017 diagnostic criteria are as follows:
== Reception == The level's originality and tonal shift caused it to stand out to critics. GamesRadar+ journalist Alex Avard praised "We Don't Go To Ravenholm..." as an example of a horror sequence in a non-horror game, describing it as "harrowing" and a "blood-soaked frightfest". Fellow GamesRadar+ journalist Ashley Reed praised the game's inclusion of "Zombie Chopper", an achievement which forced the player to beat the entire level employing only the Gravity Gun, arguing that not using weapons forced them to think creatively about how to proceed through the level, turning to items such as saw blades as improvised weaponry and employing strategies such as fleeing the zombies before they could notice the character's presence. The level was also praised for its effective use of horror elements. Den of Geek journalist Matthew Byrd described Ravenholm as "the perfect horror level", stating that it both served as a send up of horror tropes and effectively utilized them to scare the player. Suggesting that it "just happened to be the perfect idea released at the perfect time", Byrd further stated that some elements of the level "certainly don't feel quite as groundbreaking" 15 years later as they did upon the game's release. PC Gamer journalist Andy Kelly included the game on the list of his best first-person shooter levels ever, calling it "a tense, terrifying gauntlet" and "probably the best level Valve has ever designed". Screen Rant journalist Padraig Cotter argued that the level was "arguably the game's most famous" and had a "perfect balance" of horror and action.
Ranirestat (also known as AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy by Dainippon Sumitomo Pharma and PharmaKyorin. It has been granted orphan drug status. The drug is to be used orally.
Creatine is an organic acid naturally occurring in the body (and in red meats) that supplies energy to muscle cells for short bursts of energy (as required in lifting weights) via creatine phosphate replenishment of ATP. Scientific studies have shown that creatine supplementation can increase the consumer's strength, energy during performance, muscle mass, and recovery times after exercise. In addition, recent studies have also shown that creatine improves brain function and reduces mental fatigue. Some studies have suggested that consumption of creatine with protein and carbohydrates can have a greater effect than creatine combined with either protein or carbohydrates alone. While generally considered safe, long-term or excessive consumption of creatine may have an adverse effect on the kidneys, liver, or heart and should be avoided if any pre-existing conditions affecting these organs exist.
== Drawbacks == The drawbacks of the SMB are higher investment cost compared to single column operations, a higher complexity, as well as higher maintenance costs. But these drawbacks are effectively compensated by the better yield and a much lower solvent consumption as well as a much higher productivity compared to simple batch separations. For purifications, in particular the isolation of an intermediate single component or a fraction out of a multicomponent mixture, the SMB is not as ideally suited. Normally, a single SMB will separate only two fractions from each other, but a series or "train" of SMBs can perform multiple cuts and purify one or more products from a multi-component mixture. SMB is not readily suited for solvent gradients. Solvent gradient purification may be preferred for the purification of some biomolecules. A continuous chromatography technique to overcome the two fraction limit and to apply gradients is multicolumn countercurrent solvent gradient purification (MCSGP).
Sources: en.wikipedia.org
=== Post-Reynolds era and the "Slugging Seventies" (1961–1980) === John Coleman started his coaching career at Essendon in 1961, thus ending the Dick Reynolds era at the club. In the same year, Essendon finished the season mid-table, and supporters were not expecting too much for the following season. However, the club blitzed the opposition in 1962, losing only two matches and finishing top of the table. Both losses were to the previous year's grand finalists. The finals posed no problems for the resurgent Dons, easily accounting for Carlton in the season's climax, winning the 1962 Premiership by 32 points. This was a remarkable result for Coleman, who, in just his second season of coaching, claimed the ultimate prize in Australian football. As so often is the case after a flag, the following two years were below standard. A further premiership in 1965 (won from 4th position on the ladder) was also unexpected due to periods of poor form during the 1965 season. The Bombers were a different club when the finals came around, but some of the credit for the improvement was given to the influence of Brian Sampson and Ted Fordham during the finals. Coleman's time as coach turned out to be much like his playing career: highly successful but cut short when he had to stand down due to health problems in 1967. Only six years later, on the eve of the 1973 season, he died of a heart attack at just 44 years of age. Following Coleman's retirement, the club experienced tough times on and off the field.
=== Anti-resorptive drugs === Anti-resorptive drugs inhibit osteoclast differentiation and function, slowing down the breakdown of bone. They are usually prescribed for patients with osteoporosis/osteopenia, or cancer metastasis to bone , such as breast, prostate cancer and multiple myeloma. These drugs are also used for rare conditions like Paget's disease, osteogenesis imperfecta and fibrous dysplasia. The two main types of anti-resorptive drugs are bisphosphonate and denosumab. These drugs help to decrease the risk of bone fracture and bone pain. Because the mandible has poorer blood circulation, it is more affected by the effects of these drugs.
Ene-reductase (ER, ERED) is an enzyme able to catalyze the stereoselective reduction of carbon-carbon double bonds (C=C) that are activated by electron withdrawing groups (EWG), like aldehydes, ketones and esters. The catalytic cycle is dependent from the cofactor nicotinamide adenine dinucleotide phosphate (NADPH). Unlike traditional stereoselective chemical hydrogenation, that often uses noble metals and harsh conditions, ERs can operate under mild and aqueous conditions and their stereoselectivity depends on the specific enzyme.
== Definition == In vitro (Latin for "in glass"; often not italicized in English usage) studies are conducted using components of an organism that have been isolated from their usual biological surroundings. As the name suggests, in vitro experiments, colloquially "test-tube experiments", are traditionally done in glass labware, using test tubes, flasks, Petri dishes, etc. The exact scope of in vitro depends on what is considered to be in vivo (experiments done on whole living beings), and in turn what is considered to be a "whole" living being:
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.